Artal Group S.A. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001053906
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2024 · 2 positions · Total reported value $2.38B · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 33.3% · 1 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q3 2024 13F filing, Artal Group S.A. disclosed 2 equity positions with a combined reported value of $2.38B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Consumer Tilt / High Turnover.
The largest disclosed positions as of Q3 2024 were CAVA ($2.17B), LXRX ($213.80M). By sector, the heaviest allocations are Consumer Discretionary 91.0%, Health Care 9.0%. Versus the prior quarter, allocation shifted toward Consumer Discretionary (+33.4pp) and away from Technology (-1.1pp), Other (-11.1pp).
Versus the prior quarter, Artal Group S.A. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 2% of names.
Of the 8 positions fully exited versus the prior quarter, the largest were SRRK ($93.79M), KYMR ($89.72M), MORF ($86.06M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2024)
No new positions this quarter.
Fully Exited (vs previous quarter)
- SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $93.79M
- KYMR KYMERA THERAPEUTICS INC · prev qtr: $89.72M
- MORF MORPHIC HLDG INC · prev qtr: $86.06M
- APLS APELLIS PHARMACEUTICALS INC · prev qtr: $56.28M
- DYN DYNE THERAPEUTICS INC · prev qtr: $53.53M
- SLN SILENCE THERAPEUTICS PLC · prev qtr: $52.81M
- SWTX SPRINGWORKS THERAPEUTICS INC · prev qtr: $49.46M
- CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $47.75M
Insider Transactions (Form 4)
Latest Artal Group S.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-15 | Sell | CAVA GROUP, INC. | 3,000,000 | $90.30 | SEC filing |
| 2026-04-30 | Opt exercise | LEXICON PHARMACEUTICALS, INC. | 20,421,735 | — | SEC filing |
Fund Profile
Artal Group S.A. is an SEC-registered 13F filer. As of Q2 2026 it reported 2 US equity positions with a combined value of $931.12M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 2 positions · $931.12M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: CAVA (CAVA GROUP INC) at 54.9%
- Average position size: $465.56M
Sector Tilt
- Consumer Discretionary 54.9%
- Health Care 45.1%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 added, 1 reduced
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
FAQ
What did Artal Group S.A. buy in 2024-Q3?
In its 2024-Q3 13F filing, Artal Group S.A. reported 2 equity positions worth $2.38B in aggregate; its largest disclosed positions were CAVA ($2.17B), LXRX ($213.80M).
How large is Artal Group S.A.'s portfolio?
Artal Group S.A. reported $2.38B of long equity holdings across 2 positions as of 2024-Q3. Top-10 holdings account for 100.0% of reported value.
What is Artal Group S.A.'s investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Consumer Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.